Recent initiatives and strategies to developing new drugs for tropical parasitic diseases

Background: Despite the toll of tropical parasitic diseases on human life in the developing world, present therapies still rely on drugs developed decades ago. In many cases, the clinical usefulness of these compounds is limited due to poor efficacy, toxicity and the constant attrition of drug resistance. The absence of a profit incentive regarding diseases afflicting the very poor has resulted in a lack of investment by the pharmaceutical industry in new chemotherapies. Objective: Given this background, this review addresses what alternative economic and scientific strategies have been implemented to procure novel drugs. Methods: The latest chemical, genetic and screening technologies to discover and develop drugs for tropical parasitic diseases are reviewed. In many cases these strategies are being implemented within the framework of public-private partnerships established to sustain dynamic drug development portfolios. Examples of public-private partnerships and their portfolios are discussed. Further, the contribution of dedicated academic screening centres to target discovery and preclinical prosecution of new small molecules is also highlighted. In every case, the latest scientific literature is cited, but also relevant press releases and website information to indicate the present vitality in the field. Conclusion: The tools, institutions and consortia are now in place and evolving to deliver new pharmaceuticals. Short-term results have already been realised in the clinic, mainly through the provision of new formulations of existing drugs. Long-term and consistent investment will be required, however, to identify, develop and clinically validate new chemical entities.

[1]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[2]  I. Gilbert,et al.  Target assessment for antiparasitic drug discovery. , 2007, Trends in parasitology.

[3]  Solomon Nwaka,et al.  Schistosomes: challenges in compound screening , 2007, Expert opinion on drug discovery.

[4]  S. Nwaka,et al.  Challenges in drug discovery for novel antifilarials , 2007, Expert opinion on drug discovery.

[5]  W. Grant,et al.  Target identification and validation for anthelmintic discovery , 2007, Expert opinion on drug discovery.

[6]  J. Utzinger,et al.  Advances in the discovery and development of trematocidal drugs , 2007, Expert opinion on drug discovery.

[7]  N. Maina,et al.  Occurrence of multiple drug resistance in Trypanosoma brucei rhodesiense isolated from sleeping sickness patients. , 2007, The Onderstepoort journal of veterinary research.

[8]  P. Hotez,et al.  Control of neglected tropical diseases. , 2007, The New England journal of medicine.

[9]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[10]  C. Caffrey,et al.  Chemotherapy of schistosomiasis: present and future. , 2007, Current opinion in chemical biology.

[11]  M. Schlitzer,et al.  Malaria Chemotherapeutics Part I: History of Antimalarial Drug Development, Currently Used Therapeutics, and Drugs in Clinical Development , 2007, ChemMedChem.

[12]  L. Gerena,et al.  Assessment and Continued Validation of the Malaria SYBR Green I-Based Fluorescence Assay for Use in Malaria Drug Screening , 2007, Antimicrobial Agents and Chemotherapy.

[13]  D. Sereno,et al.  Advances and perspectives in Leishmania cell based drug-screening procedures. , 2007, Parasitology international.

[14]  Patrícia Cardoso Perez,et al.  Protein kinases as targets for antiparasitic chemotherapy drugs. , 2007, Current drug targets.

[15]  H. D. de Koning,et al.  Drugs and drug resistance in African trypanosomiasis. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[16]  J. Vulule,et al.  Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[17]  M. Alifrangis,et al.  Efficacies of artesunate plus either sulfadoxine–pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan , 2007, Annals of tropical medicine and parasitology.

[18]  M. Sajid,et al.  Schistosomiasis Mansoni: Novel Chemotherapy Using a Cysteine Protease Inhibitor , 2007, PLoS medicine.

[19]  J. Wiesner,et al.  Isoprenoid biosynthesis of the apicoplast as drug target. , 2007, Current drug targets.

[20]  Adam R Renslo,et al.  Drug discovery and development for neglected parasitic diseases , 2006, Nature chemical biology.

[21]  D. Wirth,et al.  High-Throughput Plasmodium falciparum Growth Assay for Malaria Drug Discovery , 2006, Antimicrobial Agents and Chemotherapy.

[22]  Solomon Nwaka,et al.  Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.

[23]  N. Quashie,et al.  A high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-1 19 kDa , 2006, Malaria Journal.

[24]  P. Clemons,et al.  Small molecules, big players: the National Cancer Institute's Initiative for Chemical Genetics. , 2006, Cancer research.

[25]  C. Caffrey,et al.  Cysteine proteinase inhibitors as therapy for parasitic diseases: advances in inhibitor design. , 2006, Mini reviews in medicinal chemistry.

[26]  J. Barnwell,et al.  Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. , 2006, The Journal of infectious diseases.

[27]  Jun O. Liu,et al.  A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.

[28]  Marcel Tanner,et al.  Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. , 2006, The Lancet. Infectious diseases.

[29]  I. Bathurst,et al.  Medicines for Malaria Venture: sustaining antimalarial drug development. , 2006, Trends in parasitology.

[30]  D. Boykin,et al.  Accumulation and Intracellular Distribution of Antitrypanosomal Diamidine Compounds DB75 and DB820 in African Trypanosomes , 2006, Antimicrobial Agents and Chemotherapy.

[31]  F. Cohen,et al.  Searching for New Antimalarial Therapeutics amongst Known Drugs , 2006, Chemical biology & drug design.

[32]  E. Torreele,et al.  Global framework on essential health R&D , 2006, The Lancet.

[33]  Beth Apsel,et al.  Discovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei , 2006, Chemical biology & drug design.

[34]  L. Matemba,et al.  Drug‐resistance of Trypanosoma b. rhodesiense isolates from Tanzania , 2006, Tropical medicine & international health : TM & IH.

[35]  J. McKerrow,et al.  A Cysteine Protease Inhibitor Protects Dogs from Cardiac Damage during Infection by Trypanosoma cruzi , 2005, Antimicrobial Agents and Chemotherapy.

[36]  S. Nwaka.  Drug discovery and beyond: the role of public-private partnerships in improving access to new malaria medicines. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[37]  Mary Moran,et al.  A Breakthrough in R&D for Neglected Diseases: New Ways to Get the Drugs We Need , 2005, PLoS Medicine.

[38]  M. Molyneux,et al.  Mutations Associated with Sulfadoxine-Pyrimethamine and Chlorproguanil Resistance in Plasmodium falciparum Isolates from Blantyre, Malawi , 2005, Antimicrobial Agents and Chemotherapy.

[39]  E. Nduati,et al.  Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[40]  D. Steverding,et al.  Anti-trypanosomal activities of DNA topoisomerase inhibitors. , 2005, Acta tropica.

[41]  D. Boykin,et al.  In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[42]  S. Croft,et al.  Public-private partnership: from there to here. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[43]  P. Rosenthal,et al.  Cysteine proteases of malaria parasites. , 2004, International journal for parasitology.

[44]  Terry K. Smith,et al.  Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness , 2004, The EMBO journal.

[45]  J. McCarter,et al.  Genomic filtering: an approach to discovering novel antiparasitics. , 2004, Trends in parasitology.

[46]  J. Karle,et al.  Synthesis of tetrasubstituted ozonides by the Griesbaum coozonolysis reaction: diastereoselectivity and functional group transformations by post-ozonolysis reactions. , 2004, The Journal of organic chemistry.

[47]  Christian Scheurer,et al.  Identification of an antimalarial synthetic trioxolane drug development candidate , 2004, Nature.

[48]  P. T. Englund,et al.  RNA interference for analysis of gene function in trypanosomatids. , 2004, Current opinion in microbiology.

[49]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[50]  P. Wilairat,et al.  Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug Screening , 2004, Antimicrobial Agents and Chemotherapy.

[51]  P. Coley,et al.  A novel DNA-based microfluorimetric method to evaluate antimalarial drug activity. , 2004, The American journal of tropical medicine and hygiene.

[52]  A. Hoerauf,et al.  Mass drug treatment for lymphatic filariasis and onchocerciasis. , 2003, Trends in parasitology.

[53]  W. Petri.  Therapy of intestinal protozoa. , 2003, Trends in parasitology.

[54]  Bill Watkins.  Drugs for the control of parasitic diseases: current status and development. , 2003, Trends in parasitology.

[55]  M. Todd,et al.  Drugs for the control of parasitic diseases: current status and development in schistosomiasis. , 2003, Trends in parasitology.

[56]  A. Fairlamb.  Chemotherapy of human African trypanosomiasis: current and future prospects. , 2003, Trends in parasitology.

[57]  J. Urbina,et al.  Specific chemotherapy of Chagas disease: controversies and advances. , 2003, Trends in parasitology.

[58]  S. Croft,et al.  Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs. , 2003, Trends in parasitology.

[59]  A. Cowman,et al.  Functional genomics: identifying drug targets for parasitic diseases. , 2003, Trends in parasitology.

[60]  J. Horton.  Human gastrointestinal helminth infections: are they now neglected diseases? , 2003, Trends in parasitology.

[61]  Michael P Barrett,et al.  The trypanosomiases , 2003, The Lancet.

[62]  Solomon Nwaka,et al.  Science & society: Virtual drug discovery and development for neglected diseases through public–private partnerships , 2003, Nature Reviews Drug Discovery.

[63]  W. Wilson,et al.  Synthesis and antiprotozoal activity of aza-analogues of furamidine. , 2003, Journal of medicinal chemistry.

[64]  T. Lang,et al.  The development of Lapdap, an affordable new treatment for malaria. , 2003, The Lancet. Infectious diseases.

[65]  Els Torreele,et al.  Drug development for neglected diseases: a deficient market and a public-health policy failure , 2002, The Lancet.

[66]  M. Lebbad,et al.  Polyclonal Plasmodium falciparum malaria in travelers and selection of antifolate mutations after proguanil prophylaxis. , 2002, The American journal of tropical medicine and hygiene.

[67]  R. Kaminsky,et al.  Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. , 2001, Microbes and infection.

[68]  C. Caffrey,et al.  Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. , 2000, Current drug targets.

[69]  Michael R. Reich,et al.  Public–private partnerships for public health , 2000, Nature Medicine.

[70]  D. Fairlie,et al.  Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. , 2000, International journal for parasitology.

[71]  H. Lichtenthaler,et al.  Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. , 1999, Science.

[72]  P. Heuveline,et al.  The burden of disease among the global poor , 1999, The Lancet.

[73]  P. Olliaro,et al.  Drug development output: what proportion for tropical diseases? , 1999, The Lancet.

[74]  B. Pécoul,et al.  Access to essential drugs in poor countries: a lost battle? , 1999, JAMA.

[75]  J. McKerrow,et al.  Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection , 1998, Journal of Experimental Medicine.

[76]  R. Kaminsky,et al.  The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. , 1997, Acta tropica.

[77]  D. Sereno,et al.  Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents , 1997, Antimicrobial agents and chemotherapy.

[78]  M. Grogl,et al.  An axenic amastigote system for drug screening , 1997, Antimicrobial agents and chemotherapy.

[79]  Arvind Kumar,et al.  Anti-pneumocystis activity of bis-amidoximes and bis-o-alkylamidoximes prodrugs , 1996 .

[80]  S. Meshnick,et al.  The mode of action of the antimalarial artemisinin and its derivatives. , 1996, General pharmacology.

[81]  R. Kaminsky,et al.  Feeder layer-free in vitro assay for screening antitrypanosomal compounds against Trypanosoma brucei brucei and T. b. evansi , 1989, Antimicrobial Agents and Chemotherapy.

[82]  K. Kinnamon,et al.  Trypanosoma rhodesiense: evaluation of the antitrypanosomal action of 2,5-bis(4-guanylphenyl)furan dihydrochloride. , 1982, Experimental parasitology.

[83]  K. Kinnamon,et al.  Leishmania donovani, Plasmodium berghei, Trypanosoma rhodesiense: antiprotozoal effects of some amidine types. , 1981, Experimental parasitology.

[84]  J. Haynes,et al.  Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique , 1979, Antimicrobial Agents and Chemotherapy.

[85]  D. Boykin,et al.  Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. , 1977, Journal of medicinal chemistry.